Lần này **Gemma 4 làm tốt hơn rõ rệt so với case trước**, nhưng vẫn có vài điểm cần ghi nhận như limitation.

**Assessment of Gemma 4 Output**

This output is much stronger than the previous one. With the richer clinical description, the model correctly shifts the top differential toward **leishmaniasis**, instead of ranking non-leishmaniasis dermatitis first. This is a more appropriate direction because the case describes a chronic progressive lesion involving the nose, nostrils, and cheek, with central erosion, raised/circinate border, pustules, immunodeficiency background, and poor response to broad-spectrum antibiotics.

The model’s strongest point is that it correctly treats the case as **decision support rather than diagnosis** and recommends confirmatory testing. This is appropriate because leishmaniasis should be confirmed by detecting the parasite or its DNA from tissue samples, such as skin lesion specimens, using microscopy, molecular methods, or culture. ([CDC][1])

The ranking is also clinically more reasonable this time. **Rank 1: mucocutaneous leishmaniasis** is plausible because the lesion involves the nose and nostrils, and the description mentions erosive lesions around the nasal area. Cutaneous leishmaniasis can present with skin sores that change over time and may have a raised edge with a central crater-like area, which partially matches the lesion morphology in this case. ([CDC][2])

However, the model may be slightly overconfident in calling it **mucocutaneous leishmaniasis**. The input mentions extension to the nostrils and nasal erosions, but it does not clearly prove deep mucosal involvement. A safer phrasing would be: **“suspected cutaneous leishmaniasis with possible mucosal/nasal involvement”** or **“suspected mucocutaneous leishmaniasis, requiring parasitological confirmation.”**

The model also does well by including opportunistic infection, fungal/bacterial infection, malignancy, autoimmune disease, and inflammatory complications in the differential. This is important because ataxia-telangiectasia is associated with immune dysfunction, recurrent infections, and increased lymphoma risk. ([Merck Manuals][3])

The main weakness is the **retrieval-generation mismatch**. The retrieved evidence mainly supports **cutaneous leishmaniasis**, not specifically mucocutaneous leishmaniasis. The retrieval audit shows a local lexical retriever, only three candidates, and no live reranker. Therefore, the model’s final MCL conclusion appears partly generated from clinical reasoning rather than strongly grounded in retrieved MCL evidence.

**Conclusion:**
Gemma 4 performs **substantially better in this second run**. It correctly identifies leishmaniasis as the leading concern, gives a reasonable medium confidence, and keeps the answer clinically cautious. The main correction is that the output should avoid sounding too certain about **mucocutaneous** disease unless mucosal involvement is confirmed. The best label would be:

**“Suspected cutaneous leishmaniasis with possible nasal/mucosal involvement; mucocutaneous leishmaniasis should be considered, but confirmation by smear, biopsy, culture, or PCR is required.”**

[1]: https://www.cdc.gov/leishmaniasis/hcp/diagnosis/index.html?utm_source=chatgpt.com "Clinical Testing and Diagnosis for Leishmaniasis"
[2]: https://www.cdc.gov/dpdx/leishmaniasis/index.html?utm_source=chatgpt.com "DPDx - Leishmaniasis"
[3]: https://www.merckmanuals.com/home/immune-disorders/immunodeficiency-disorders/ataxia-telangiectasia?utm_source=chatgpt.com "Ataxia-Telangiectasia - Allergies and Immune Disorders"
